Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer

Table 1 Baseline data of the colorectal cancer cohort included in this study

Baseline data	Control group (n = 55)	Research group (n = 66)	χ2/t	P value
Age (years), mean ± SD	57.09 ± 7.75	56.41 ± 11.14	0.382	0.703
Sex, n (%)			0.111	0.740
Male	30 (54.55)	34 (51.52)
Female	25 (45.45)	32 (48.48)
Onset site, n (%)			0.186	0.666
Colon	27 (49.09)	35 (53.03)
Rectum	28 (50.91)	31 (46.97)
Pathological type, n (%)			0.043	0.836
Adenocarcinoma	49 (89.09)	58 (87.88)
Other	6 (10.91)	8 (12.12)
Clinical stage, n (%)			0.029	0.864
II	35 (63.64)	41 (62.12)
III	20 (36.36)	25 (37.88)
Differentiation, n (%)			0.021	0.885
Moderately- or well-differentiated	39 (70.91)	46 (69.70)
Poorly differentiated	16 (29.09)	20 (30.30)

Table 2 Efficacy of the postoperative treatments in the two colorectal cancer patient groups, n (%)

Curative effect	Control group (n = 55)	Research group (n = 66)	χ2	P value
Survival	36 (65.45)	54 (81.82)
Recurrence/metastasis/death	19 (34.55)	12 (18.18)
Two-year disease-free survival	36 (65.45)	54 (81.82)	4.215	0.040

The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen.

Table 3 Univariate analysis of the variables that mediate postoperative treatment efficacy in colorectal cancer patients, n (%)

Baseline data	Effective treatment group (n = 90)	Ineffective treatment group (n = 31)	χ2	P value
Age (years)			0.402	0.526
< 60	58 (64.44)	18 (58.06)
≥ 60	32 (35.56)	13 (41.94)
Sex			0.340	0.560
Male	49 (54.44)	15 (48.39)
Female	41 (45.56)	16 (51.61)
Onset site			0.216	0.642
Colon	45 (50.00)	17 (54.84)
Rectum	45 (50.00)	14 (45.16)
Pathological type			0.072	0.788
Adenocarcinoma	80 (88.89)	27 (87.10)
Other	10 (11.11)	4 (12.90)
Clinical stage			10.363	0.001
I-II	64 (71.11)	12 (38.71)
III	26 (28.89)	19 (61.29)
Differentiation			12.550	< 0.001
Moderately- or well-differentiated	71 (78.89)	14 (45.16)
Poorly differentiated	19 (21.11)	17 (54.84)
Treatment approach			4.215	0.040
XELOX	36 (40.00)	19 (61.29)
XELOX + DC-CIK	54 (60.00)	12 (38.71)

DC-CIK: Dendritic cell-cytokine-induced killer.

Table 4 Multivariate analysis of the variables that mediate postoperative treatment efficacy in colorectal cancer patients

Variable	β	SE	Wald	P value	OR	95%CI
Clinical stage	0.114	0.443	0.066	0.797	1.121	0.470-2.673
Differentiation	−0.056	0.473	0.014	0.905	0.945	0.374-2.390
Treatment approach	0.867	0.427	4.115	0.042	2.379	1.030-5.495

95%CI: 95%confidence interval; OR: Odds ratio; SE: Standard error.

Table 5 Adverse events in the two colorectal cancer treatment groups, n (%)

Adverse event	Control group (n = 55)	Research group (n = 66)	χ2	P value
Diarrhea	11 (20.00)	5 (7.58)	4.036	0.045
Myelosuppression	20 (36.36)	10 (15.15)	7.239	0.007
Gastrointestinal reaction	19 (34.55)	9 (13.64)	7.374	0.007
Peripheral neuritis	7 (12.73)	2 (3.03)	4.097	0.043

The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen.